Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus

Source Summary

Pratteln, Switzerland, July 13, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE® (vamorolone), extending the partnership to include Georgia, Kazakhstan, Belarus, Azerbaijan and Uzbekistan, for the treatment of Duchenne muscular dystrophy (DMD) in patients two years of age and older.